Firm
Ruth Hoy will join the firm's IP practice alongside Huw Cookson, who will also become a partner
IP boutique firm says its platform will help navigate ‘scattered’ decisions by bringing case law, commentary and research under one umbrella
The latest round of promotions has contributed to a 21% rise in partner headcount in the past two years, with business leaders eyeing litigation and the UPC
Sim & San, which secured the $16m victory for their client, previously led Communications Components Antenna to a $26m damages win in 2024
Sponsored
Sponsored
-
Sponsored by Berken IPMaría Aurora García of Berken IP examines how Argentine courts are using dynamic injunctions to tackle illegal sports streaming, particularly in the context of major events such as the football World Cup
-
Sponsored by Bird & BirdAnnika Lückemann and Jan van Dieck of Bird & Bird analyse the Unified Patent Court’s opening ruling concerning a supplementary protection certificate, highlighting procedural peculiarities, urgency considerations, and possible implications for pharmaceutical originator-generic disputes
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Parth Bajaj of RNA, Technology and IP Attorneys analyse new obligations concerning synthetically generated information, accelerated takedown provisions, and safe harbour implications amid rising SGI-driven scams
-
Sponsored by Tilleke & GibbinsLoc Xuan Le of T&G Law Firm LLC (TGVN), the local associate firm of Tilleke & Gibbins, outlines key amendments to Vietnam’s Law on Intellectual Property concerning AI use of protected IP objects
-
Sponsored by Tilleke & GibbinsWiramrudee (Pink) Mokkhavesa and Tanapong Pongburanakit of Tilleke & Gibbins say Thai courts’ evolving approach to criminal intellectual property damages enables brand owners to enhance return on investment in raids and avoid civil litigation
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceutical use claims in China